Differences in RNA and microRNA Expression Between PTCH1- and SUFU-mutated Medulloblastoma

SIVAN GERSHANOV^{1*&}, HELEN TOLEDANO^{2,3*}, NOMI PERNICONE¹,
SUZANA FICHMAN^{3,4}, SHALOM MICHOWIZ^{3,5}, ALBERT PINHASOV¹,
NITZA GOLDENBERG-COHEN^{6,7,8}, TAMAR LISTOVSKY^{1,9} and MALI SALMON-DIVON^{1,9}

¹Department of Molecular Biology, Ariel University, Ariel, Israel;

²Department of Pediatric Oncology, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel;

³Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel;

⁴Department of Pathology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel;

⁵Department of Pediatric Neurosurgery, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel;

⁶Department of Ophthalmology, Bnai Zion Medical Center, Haifa, Israel;

⁷The Krieger Eye Research Laboratory, Felsenstein Medical Research Center,
Medical Center, Petah-Tikva, Israel;

⁸The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel;

⁹Adelson School of Medicine, Ariel University, Ariel, Israel

Abstract. *Background/Aim:* Germline mutations in *PTCH1* or *SUFU* in the sonic hedgehog (*SHH*) pathway cause Gorlin's syndrome with increased risk of developing *SHH*-subgroup medulloblastoma. Gorlin's syndrome precludes the use of radiotherapy (a standard component of treatment) due to the development of multiple basal cell carcinomas. Also, current *SHH* inhibitors are ineffective against *SUFU*-mutated medulloblastoma, as they inhibit upstream genes. In this study, we aimed to detect differences in the expression of genes and microRNAs between *SUFU*- and *PTCH1*-mutated *SHH* medulloblastomas which may hint at new treatment directions. *Patients and Methods:* We sequenced RNA and microRNA from tumors of two patients with germline Gorlin's syndrome

– one having *PTCH1* mutation and one with *SUFU* mutation – followed by bioinformatics analysis to detect changes in genes and miRNAs expression in these two tumors. Expression changes were validated using qRT-PCR. Ingenuity pathway analysis was performed in search for targetable pathways. *Results:* Compared to the *PTCH1* tumor, the *SUFU* tumor demonstrated lower expression of miR-301a-3p and miR-181c-5p, matrix metalloproteinase 11 (*MMP11*) and *OTX2*, higher expression of miR-7-5p and corresponding lower expression of its targeted gene, connexin 30 (*GJB6*). We propose mechanisms to explain the phenotypic differences between the two types of tumors, and understand why *PTCH1* and *SUFU* tumors tend to relapse locally (rather than metastatically as in other medulloblastoma subgroups). *Conclusion:* Our results help towards finding new treatable molecular targets for these types of medulloblastomas.

This article is freely accessible online.

*These Authors contributed equally to this work.

&Current address: Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.

Correspondence to: Mali Salmon-Divon, Department of Molecular Biology, Building 29 room 29A 2.8B, Ariel University, Ariel, 40700, Israel. Tel: +972 546350197, e-mail: malisa@ariel.ac.il and Tamar Listovsky, Department of Molecular Biology, Building 29 room 29A 1.9, Ariel University, Ariel 40700, Israel. Tel: +972 39143038, e-mail: tamary@ariel.ac.il

Key Words: Gorlin syndrome, medulloblastoma, *PTCH1*, Sonic Hedgehog, *SUFU*.

Basal cell nevus syndrome, also known as Gorlin syndrome (GS) increases the risk of developing odontogenic jaw keratocysts, skeletal abnormalities (1, 2), basal cell carcinoma (BCC) of the skin [in areas that have undergone radiation (1)], and medulloblastomas (MBs) by the age of five years (2). The most common cause of GS is a heterozygous germline mutation in the Patched (*PTCH1*) gene (3), but germline mutations in the *SUFU* gene have also been found to cause GS (4). Up to 5% of individuals with GS develop childhood *SHH*-MB (4); therefore, children with germline mutations are recommended to undergo periodic MRI screening of the brain until the age of eight years (5).

Both PTCH1 and SUFU are vital players in the activation of the sonic hedgehog (SHH) pathway, which is one of the main trafficking networks that regulate events during embryonic development, and aberrations in its regulation may cause congenital disabilities and cancer. Activation of the SHH signaling pathway is mediated by the receptor Smoothened (SMO). When the SHH ligand is low or absent ("off-state"), SMO transports to the membrane, where its activity is inhibited by Patched (PTCH1). The downstream effectors are inhibited via SUFU, resulting in inhibition of target gene expression. When SHH binds to Patched ("on-state"), SMO levels increase, and SUFU is deactivated, leading to activation of gene expression, resulting in cell growth and the patterning of multicellular embryos (6).

One of the four subgroups of MB – the most common malignant brain tumor in children (7) – is the SHH subgroup, which is most frequent in infants (<3 years old) and young adults (>16 years old). Mutations in PTCH1 or SUFU are frequent in the tumors of infants with SHH-MB (8). Although most of these mutations are sporadic, SUFU and PTCH1 germline mutations can be detected in 2% of all patients with MB, exclusively in the SHH subgroup (9). The risk of developing MB has been suggested to be 20 times higher in germline SUFU mutations and at a younger age than germline PTCH1 mutations (4, 10). MBs with a germline SUFU mutation show poor prognosis with overall survival rate of 66% (10), which is much lower than the >90% overall survival rate reported for desmoplastic MB in young children (11). These children often demonstrate local relapse with progression-free survival of 42% at five years, and they will most likely need radiation for salvage therapy (10).

Standard MB therapy for children over three years old includes surgical resection, upfront craniospinal irradiation, chemotherapy, and high-dose chemotherapy with hematopoietic stem cell rescue in high-risk patients (12). Due to the enormous cognitive damage of radiation in infants, treatment is usually based on chemotherapy alone. However, some children will relapse or progress and would need subsequent radiation therapy. Children undiagnosed with GS will develop hundreds to thousands of BCCs in the irradiated areas. Therefore, it is vital to identify those children with germline PTCH1/SUFU mutations to avoid irradiation at all costs.

Recently, new SHH inhibitors have been developed for the treatment of SHH-MB (13). However, these are SMO inhibitors and, therefore, will only inhibit the upstream activation of the pathway – *e.g.*, at the level of PTCH1 or SMO – and will not affect downstream mutations, such as SUFU (14). Also, the SMO inhibitors cause irreversible growth plate fusion in children and, therefore, clinical studies are employing these agents for skeletally mature children only (15). There is a desperate need for new therapies for young children with GS-SHH-MB that should avoid radiation therapy, and, in particular children with germline SUFU mutation, who will not respond to SMO inhibitors.

We aimed to find new potential molecules such as microRNAs (miRs), to serve as diagnostic biomarkers or as drug targets (16, 17). miRs are short noncoding RNAs, which play an essential role in gene translational regulation. Moreover, miRs can be used to define specific signatures for individual cancers and cancer stages (18, 19), including for MB subgroup classification (20).

In this study, we searched for targetable pathways in the tumors of two patients diagnosed with SHH-MB, one with a germline SUFU mutation and the other with a germline PTCH1 mutation. We aimed to detect similarities and differences at the expression levels of genes and miRs to better understand the biology of these two tumors that could help develop targets for future clinical use.

Patients and Methods

Patients and tumor collection. The study design adhered to the tenets of the Declaration of Helsinki and approved by the institutional and national review board of the Israel Ministry of Health. Informed consent was obtained. Primary tumor samples were collected at surgery, placed in RNAlater™ (AM7020; Thermo Fisher Scientific, Waltham, MA, USA), and stored at –80°C.

RNA and microRNA extraction and sequencing. Total RNA was extracted from freshly frozen tumor tissue samples as previously described (20). Library preparation and sequencing was performed using the Illumina TruSeq protocol on the HiSeq 2500 machine. Raw data deposited at the Sequence Read Archive (SRA) accession number SRP095882. The PTCH1-MB was included in our previous study (SRS1888277) (20) while SUFU-MB is newly deposited (SRS3694085).

RNA-seq data analysis. Raw reads were processed and analyzed as previously described (20). To obtain dispersion estimates for a count dataset, we used the 'estimateDispersions' function in the DESeq R package (21). Since we had no replicates, we defined the argument method="blind", which ignored the sample labels and computed the empirical dispersion value of the gene as if the two samples were replicates of a single condition. The argument sharing Mode was defined as "fit-only". Genes with FDR corrected $p < 0.05$ were noted as displaying different expression levels.

MicroRNA-seq data analysis. Raw reads were processed and analyzed as previously described (20). Unless specified otherwise, a p -value of 0.05 was used as the significance cutoff.

Ingenuity pathway analysis (IPA). Genes with FDR < 0.05 and miRs with $p < 0.05$ were uploaded to QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>) software (22). The IPA was used to gain insights into the overall biological changes introduced by the expression, miR target gene prediction, and miR and gene Integrated Analysis. Using the Ingenuity Pathways Knowledge Base, each gene was linked to specific functions, pathways, and diseases.

Analysis of an independent microarray data. The dataset GSE85217 (23) downloaded from the Gene Expression Omnibus (GEO) database

(24), comprises 763 samples of which 223 are SHH. There is no information regarding germline mutations in the database, hence we had to choose the samples with the highest probability of representing GS patients. The likelihood of developing MB in patients with GS is higher in younger children (2), and as we were interested in SHH-MBs that are as similar as possible to those examined in our study, we first selected tumors from children under three years of age. Then we selected only those with a deletion in 10q, which includes the SUFU gene (n=3), and those with a deletion in 9q, which contains the PTCH1 gene (n=13). In this way we can compare tumors with similar mutations to ours, even if this is just in the tumor and not in the germline. We employed a moderated *t*-test, conducted using the limma (25) R package (version 3.38.3). Deletions, histology, and age were included as covariates in the linear model, and an FDR-corrected *p*-value of 0.05 was used as the significance cutoff.

Cell culture and siRNA transfections. Daoy cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Biological Industries Israel, Beit Haemek; 01-052-1A) with 4.5 g/l D-glucose, 4 mM L-glutamine, 10% fetal bovine serum (Biological Industries Israel; 04-007-1A), and 1% penicillin/streptomycin. Dicer-substrate 27mer short interfering RNAs (DsiRNAs) targeting human SUFU (hs.Ri.SUFU.13.1, hs.Ri.SUFU.13.2) and PTCH1 (TriFECTa RNAi kit, hs.Ri.PTCH1.13) were pre-designed by and purchased from IDT. The cells were transfected with siRNA at a final concentration of 30 nM per siRNA (SUFU siRNA, PTCH1 siRNA, or Scramble siRNA for control) by using the Avalanche® Everyday Transfection Reagent (EZT-EVDY-1), according to the manufacturer's protocol. Briefly, the cells were passaged one day before transfection to reach a confluency of 60-70%. The next day, the selected siRNA was incubated in a serum-free medium with the recommended volume of transfection reagent for 20 min at room temperature. The transfection mixture was gently added to the prepared cell culture plate(s) for continued incubation at 37°C for 24-36 h, until harvesting and RNA extraction.

Reverse transcription (RT) and quantitative PCR (qPCR). Total RNA was isolated from Daoy cells by using the NucleoZol homogenizing reagent (Machery-Nagel 740404.200), according to the manufacturer's protocol. Purified RNA samples were reverse-transcribed using the GoScript Reverse Transcription System (Promega, Madison, WI, USA, A5000) according to the manufacturer's protocol. The cDNA product was diluted 1:5 and mixed with SYBR Green PCR Master Mix (ThermoFisher Scientific) for amplification on an AriaMX thermal cycler (Agilent Technologies, Santa Clara, CA, USA) using the gene-specific primer sets described below. Each qPCR reaction had a total volume of 12 µl. Three biological replicates were performed, and all reactions were run in triplicates. The comparative Ct method was used to analyze mRNA levels, using actin as the normalization control.

Primers used for qPCR reaction were: SUFU 5' CAGCA AACCTGTCCTTCCACCA 3' CAGATGTACGCTCTCAAGCTGC, PTCH1 5' GCTGCACTACTTCAGAGACTGG 3' CACCAGG AGTTTGTAGGCAAGG, MMP11 5' GAGAAGACGGACCT CACCTACA 3' CTCAGTAAAGGTGAGTGGCGTC, FOXL2 5' CGGAGAAGAGGCTCACGCTGT 3' CTGAGGTTGTGGCGGAT GCTAT, GSTM1 5' CTATGATGTCCTTGACCTCCACCGTATA 3' ATGTTACGAAGGATAGTGGGTAGCTGA, GABRA4 5' TC CTGGACAGTTTGTCTCGATGG 3' CAGAAACAGGTCCAAAG CTGGTG, NPNT 5' GTAAGCACAGGTGCATGAACA 3' GA ACCATCCGGCATGAGCATA.

Results

Patients. Primary tumor samples were obtained from two children diagnosed with non-metastatic, desmoplastic MB. Both tumors were identified as belonging to the SHH subgroup by using nanoString nCounter Technology, as previously described (26).

Patient 1: A boy, the first child of Yemenite origin parents who are not relatives, with no family history of cancer. Neonatal follow-up showed large head circumference with continued growth on the 98% percentile. There was some delay in motor and speech development. The boy was noted to have torticollis, unilateral dilation of the renal pelvis, and trivial pulmonary stenosis. At age 22 months, he presented a two-week history of recurrent falls followed by vomiting and apathy. MRI at diagnosis (Figure 1B and C) showed a large heterogeneous mass in the cerebellar vermis with obstructive hydrocephalus. No metastatic spread to the craniospinal axis was evident. The patient underwent gross total removal of the tumor, and pathology showed desmoplastic medulloblastoma (Figure 1F). Genetic testing was performed due to macrocephaly and showed a *de novo* germline mutation in PTCH1 NM_000264.5(PTCH1):c.379G>T (p.Glu127*) (Figure 1A). The boy was treated according to the COG 99703 protocol without irradiation. He is currently 10 years old, with no evidence of relapse. He developed keratogenic jaw cysts at the age of 5 years and has mild learning difficulties. He has palmar pits and multiple melanocytic nevi.

Patient 2: A girl, the fourth child of unrelated parents of Iraqi-Moroccan/Yemenite origin, with no family history of malignancy. At age 3 months, the local well bay clinic noticed increasing head circumference, new-onset strabismus, and lethargy. MRI (Figure 1D and E) showed extreme hydrocephalus and a multicystic mass in the posterior fossa (PF). There were no metastases visible in the brain or spine. She underwent partial resection of the mass, leaving a supratentorial residue. The pathology result was MB with extensive nodularity (MBEN) (Figure 1G). The tumor was positive for both GAB1 and YAP in more than 80% of cells. Due to her extremely young age, she underwent genetic testing, which showed a *de novo* heterozygous loss of exon 3 in the SUFU gene at the DNA level. She was treated according to the ACNS 1221 protocol (before suspension of enrolment) without intrathecal chemotherapy. She is now 6 years and four months old, with no evidence of relapse. She shows some residual mild ataxia and dysmetria and attends a regular kindergarten. She has no other physical findings of GS.

Expression profiling of genes. Comparison of SUFU-MB against PTCH1-MB detected 111 genes displaying different expression levels. Of these 23 were up-regulated, and 88 were down-regulated in SUFU-MB, compared to PTCH1-MB

Figure 1. (A) Sequence chromatograms, showing the heterozygous *PTCH1* *de novo* germline mutation NM_000264.5(*PTCH1*): c.379G>T (p.Glu127*) in patient 1 (p1), and the non-carrier mother (m) and father (f) of the patient, as well as a control from an unrelated individual (con). (B-E) MRI images at diagnosis, showing the tumor (short, thick arrows) and severe hydrocephalus (long, thin arrows): (B-C) patient 1, *PTCH*-MB, (D-E) patient 2, *SUFU*-MB. (B) Axial T2WI image and (C) sagittal T1WI post-Gadolinium image, showing a large 3.2×4.5×4.4 cm heterogeneous mass in the cerebellar vermis on T2, invading the 4th ventricle. The mass is enhanced and has areas of restriction and necrosis with secondary obstructive hydrocephalus. (D) Axial T2WI image and (E) sagittal T1WI post-Gadolinium image, showing extreme hydrocephalus caused by the large 3.5×6×6 cm mass in the posterior fossa (PF) and surrounding edema. The tumor was localized centrally in the PF, with the involvement of the superior portion of the 4th ventricle with cranial extension. The tumor is multicystic with multiple enhancing tumor nodules and restricted on diffusion. (F-G) H&E preparation from the *PTCH*-MB tumor of patient 1 (F), showing nodular, reticulin-free zones surrounded by densely packed undifferentiated cells with hyperchromatic nuclei producing a dense intercellular reticulin network. Macrophages and stroma were inconspicuous. The preparation from the *SUFU*-MB tumor of patient 2 (G) shows a prominent lobular architecture, large reticulin-free zones, and is rich in neuroepithelial-like tissue. These zones showed population by cells with neurocytic differentiation. Macrophages and stroma were inconspicuous.

(Figure 2A). The up-regulated cluster was associated with extracellular matrix organization and cell adhesion, while the down-regulated cluster was associated with complement activation (classical pathway) and immune system processes.

Of the MB-related genes, we detected a significantly lower expression of *OTX2* in the *SUFU*-mutated tumor. *OTX2* plays an essential role in normal cerebellar development (27) and aberrant *OTX2* expression is implicated in several malignancies

Figure 2. (A) A Heatmap of 23 up-regulated genes (red) and 88 down-regulated genes (blue) in the SUFU-MB compared to the PTCH1-MB. Heatmap was generated with heatmap3 (51) using complete as the linkage method, and Euclidean as the distance. (B) MicroRNAs expression in network no. 1 (Table III). (C) Gene and miR inverse expression in the SUFU-MB as compared with the PTCH1-MB. Green nodes represent decreased expression and red nodes represent increased expression. White nodes represent no significant change in expression. Pink line indicates diseases or functions related to the molecules. CO: Correlation, C: causation/leads. The figures were generated using Ingenuity® Pathway Analysis.

(28), including MB (29). Indeed, lower OTX2 expression is one of the biomarkers used to differentiate SHH-MB from other MB subgroups in a real-time PCR assay panel (30). In MB, the effect of overexpressed OTX2 as an oncogene is predominantly

observed in Group 3/4, and participates in tumor localization and migration (28). In contrast, in SHH tumors, overexpression of OTX2 inhibits tumor progression (27). The lower expression of OTX2 may contribute to the increased risk of local relapse

Table I. Top five canonical signaling pathways identified by the ingenuity pathway analysis (IPA) for the genes whose expression differs between the two patients.

Canonical pathways	p-Value	Molecules
Communication between innate and adaptive immune cells	<0.001	HLA-G, IGHG3, IGHM, IGHG1, HLA-DRB5
Autoimmune thyroid disease signaling	<0.001	HLA-G, IGHG3, IGHG1, HLA-DRB5
Primary immunodeficiency signaling	<0.001	IGHG3, IGLL1/IGLL5, IGHM, IGHG1
Allograft rejection signaling	<0.001	HLA-G, IGHG3, IGHG1, HLA-DRB5
Hematopoiesis from pluripotent stem cells	<0.001	IGHG3, IGHM, IGHG1

and, therefore, to poorer event-free survival which has been found in SUFU-mutated patients (10).

Recently, mTORC1 signaling was detected as a downstream effector of OTX2 in Group 3 MB (31). A relationship between mTOR pathway and SHH was also demonstrated for SHH MB (32, 33). However, the mTOR signaling molecules did not show differential expression between the two patients, demonstrating that mTOR probably does not have a role in regulating the pathophysiology differences of the two SHH tumors.

We found a decreased expression of matrix metalloproteinase 11 (MMP11) in SUFU-MB, compared to PTCH1-MB. MMPs are endopeptidases, responsible for the degradation of extracellular matrix components (34) and play a significant role in cancer (35). Increased expression of some MMPs, including MMP11, are correlated with the tumor WHO-grading classification of human malignant gliomas (36). It will be of interest to test whether the expression of MMPs contributes to the increased probability of local relapse in SHH tumors.

Immune signaling pathways dominated the list of genes whose expression differed between the tumors from the two patients (Table I).

Over-represented diseases and biological functions included skeletal and muscular disorders, cell death and survival, embryonic development, and nervous system development and function (Table II).

Top associated network functions included cancer-related functions, such as cellular development, DNA replication, recombination, and repair (Table III).

Genes belonging to these networks include OTX2 and MYC, which are part of the expression panel used to differentiate MB subgroups (30). The genes GSTM1 and HLA-G, which belong to network number 2 (Table III), are known to be associated with BCC. Genetic variants in GSTM1 might contribute to the variation in the number of BCC jaw cysts and its presentational phenotypes in patients with PTCH-mutated as opposed to SUFU- mutated GS (37), while the expression of the HLA-G gene is high in BCC and decreases following radiotherapy (38).

Expression profiling of microRNAs. Overall, 778 miRs were expressed in both tumors, of which the expression level of 11

Table II. Top diseases and biological functions identified by the ingenuity pathway analysis (IPA), for the genes whose expression differs between the two patients.

	p-Value	Number of molecules
Diseases and biological functions		
Metabolic disease	0.039-<0.001	16
Neurological disease	0.045-<0.001	27
Skeletal and muscular disorders	0.039-<0.001	27
Developmental disorder	0.046-<0.001	20
Hereditary disorder	0.043-<0.001	28
Molecular and cellular functions		
Cell death and survival	0.041-<0.001	7
Cellular assembly and organization	0.035-<0.001	12
Cell cycle	0.035-0.003	4
Cell morphology	0.029-0.003	3
Cellular function and maintenance	0.035-0.003	9
Physiological system development and function		
Embryonic development	0.048-0.001	13
Nervous system development and function	0.048-0.001	7
Organ development	0.048-0.001	11
Organismal development	0.048-0.001	14
Tissue development	0.048-0.001	11

miRs was different between SUFU-MB and PTCH1-MB, three miRs displayed higher expression and eight lower expression levels (Table IV). IPA analysis of differentially expressed miRs identified cancer-related functions, such as cell morphology, cellular development, and cellular growth and proliferation as top diseases and biological functions (Table V).

Top network functions included RNA post-transcriptional modification and cancer, cardiovascular diseases, and connective tissue disorders (Table VI). Among the miRs that showed a lower expression in SUFU-MB were miR-301a-3p and miR-181c-5p. These miRs are related to early stages of solid tumor processes and the processing of siRNA networks, and they regulate, either directly or indirectly, the expression of DICER1 (Figure 2B).

Table III. Top five associated network functions identified by the ingenuity pathway analysis (IPA) for the genes whose expression differs between the two patients.

ID	Network	Score	Molecules in network
1	Cellular development, reproductive system development and function, DNA replication, recombination, and repair	30	<i>ATP2A3, CDH12, CHI3L1, COL1A1, CPM, CTNBN1, DLX2, EGFR, FOS, FOXL2, FSH, GJA1, GRP, IGHG1, IL1B, LDLR, MAFF, MMP11, MT-CO2, MT-TE, MT-TY, MYC, NEB, NFATC2, OTX2, PCP4L1, PGR, PPP1R1A, PTGS2, SBDS, SMARCA4, SORCS1, SPI, STAT5A, YAP1</i>
2	Endocrine system disorders, gastrointestinal disease, metabolic disease	27	<i>ATP2A2, BMP2, BMP7, COL1A1, COL1A2, COL3A1, COL4A6, DLX5, FAP, GSTM1, HLA-G, Histone h3, IGHM, IGLL1/IGLL5, IL6, INS, Interferon alpha, LDLR, LOC102724428/SIK1, NKX2-2, NKX2-3, NRXN1, NUPR1, PLA2G2A, POU5F1, PPARG, S100A4, SHOX2, SLC6A3, TBX5, TFAP2A, TGFB1, TPM1, TTR, XIST</i>
3	Cancer, cardiovascular disease, cardiovascular system development and function	2	<i>AGTR1, IGKV1-5</i>
4	Dermatological diseases and conditions, developmental disorder, hereditary disorder	2	<i>GJB6, KRT14</i>
5	Antimicrobial response, carbohydrate metabolism, cardiovascular disease	2	<i>DDX3Y, LDLR</i>

Table IV. MicroRNAs displayed different expression levels SUFU-MB compared to those expressed in PTCH1-MB.

MicroRNA ID	Log2 fold change	p-Value	Regulation
hsa-miR-301a-3p	-7.674	0.021	Down
hsa-miR-1307-5p	-7.197	0.028	Down
hsa-miR-4454	-6.868	0.041	Down
hsa-miR-99a-3p	-6.789	0.032	Down
hsa-miR-135a-3p	-6.655	0.039	Down
hsa-miR-4485-3p	-6.577	0.036	Down
hsa-miR-181c-5p	-6.174	0.048	Down
hsa-miR-4286	-6.124	0.050	Down
hsa-miR-379-5p	6.329	0.041	Up
hsa-miR-129-5p	8.066	0.018	Up
hsa-miR-7-5p	10.602	0.005	Up

Integrated analysis of miRs and mRNA expression. Of the 111 differentially regulated genes, 16 are targets for the 11 miRs. Of these, nine target genes demonstrated an inverse expression with six miRs (Table VII, Figure 2C). We found that miR-301a-3p demonstrates lower expression levels in SUFU-MB, compared to PTCH1-MB. miR-301a-3p acts as an oncomiR (39, 40), as it down-regulates the expression of the SMAD4 gene. Inhibiting miR-301a-3p reversed gemcitabine treatment resistance in pancreatic cancer cells *in vitro* by regulating the expression of PTEN (41). The role of miR-301a-3p in MB is yet unclear, and it may have different effects in different tissues. One of the target genes of miR-301a-3p is GABRA4, which is downregulated in MB (42). We found that the expression of GABRA4 was higher

Table V. Top diseases and biological functions identified by the ingenuity pathway analysis (IPA) for the miRs represented different expression in our patients.

	p-Value	Number of molecules
Diseases and biological functions		
Cancer	0.044-<0.001	5
Organismal injury and abnormalities	0.044-<0.001	5
Reproductive system disease	0.003-<0.001	3
Gastrointestinal disease	0.033-<0.001	3
Respiratory disease	0.008-<0.001	4
Molecular and cellular functions		
Cell morphology	0.007-0.001	1
Cellular function and maintenance	0.007-0.001	1
Cellular development	0.016-0.002	4
Cellular growth and proliferation	0.014-0.002	4
Cellular movement	0.037-0.002	3
Physiological system		
development and function		
Cardiovascular system development and function	0.005	1
Embryonic development	0.005	1
Organismal development	0.005	1
Tissue development	0.005	1
Connective tissue development and function	0.006	1

in SUFU-MB, possibly resulting from the lower expression of its regulator, miR-301a-3p. GABRA4 is a part of the GABA receptor signaling pathway and, considering our

Table VI. Top three associated network functions identified by the ingenuity pathway analysis (IPA) for the miRs represented different expression in our patients.

ID	Network	Score	Molecules in network
1	RNA post-transcriptional modification, cancer, organismal injury and abnormalities	9	AGO2, DICER1, estrogen receptor, EZH2, miR-301a-3p, miR-181a-5p, miR-7-5p
2	Cardiovascular disease, connective tissue disorders, dermatological diseases and conditions	3	IL17A, miR-129-5p
3	Respiratory disease, organ morphology, organismal injury and abnormalities	3	ILF3, miR-135a-3p

Table VII. MicroRNAs and their targeted genes that exhibit inverse expression, predicted by ingenuity pathway analysis (IPA).

MicroRNAs	Expr. Log Ratio	Target gene ^a	Expr. Log ratio	Pathway ^b
miR-301a-3p	-7.674	GABRA4	5.644	GABA receptor signaling, neuroinflammation signaling pathway Aryl hydrocarbon receptor signaling, glutathione redox reactions i, glutathione-mediated detoxification, LPS/IL-1 mediated inhibition of RXR function, NRF2-mediated oxidative stress response, PXR/RXR activation, xenobiotic metabolism signaling
miR-301a-3p	-7.674	GSTM1	5.21	
miR-301a-3p	-7.674	NPNT	5.567	GPCR-mediated integration of entero-endocrine signaling exemplified by an L cell Gap junction signaling
miR-379-5p	6.329	FOXL2	-5.821	
miR-4286	-6.124	PCP4L1	5.89	
miR-4454	-6.868	GRP	8.817	
miR-7-5p	10.634	GJB6 (Connexin30)	-6.186	Oncostatin M signaling
miR-7-5p	10.634	PVALB	-5.306	
miR-99a-3p	-6.789	CHI3L1	6.471	

^aTarget association based on Ingenuity "target filter" annotation, where only "highly predicted" and "moderate predicted" targets were used.

^bPathways according to Ingenuity core analysis of the targets.

findings; it may not be downregulated in all MBs as previously thought. The specific role of GABRA4 in MB tumorigenesis, in general, or in SUFU-mutated MB is yet to be determined.

The expression level of miR-7-5p was higher in SUFU-MB than in PTCH1-MB and, correspondingly, the expression of its target gene, Connexin 30 (GJB6), was lower. Connexins play a role in the gap-junction signaling pathway, and they function as tumor suppressors (43). The expression of Connexin 30 in human glioblastoma cells was found to reduce their growth *in vitro*, but, at the same time, it made them resistant to the effects of radiation therapy (44). Increasing the levels of Connexin 30 in SUFU tumors may serve as a therapeutic option to decrease cell proliferation, while resistance to radiation therapy will be irrelevant in these young patients, whose up-front treatment is planned to be radiation-free.

MiR-379-5p showed higher expression in the SUFU-MB, compared to the PTCH1-MB, while its targeted gene, FOXL2, demonstrated lower expression levels. FOXL2 is a transcription factor involved in congenital disorders (45). It

directly modulates the expression of the estrogen receptor 2 (ESR2) (46). A recent study found that 17 β -estradiol, via ESR2, exerts chemoprotective effects in some MB cell lines (47). In the SHH pathway, SUFU and GLI interact and bind to PIAS1 (48), which activates estrogen receptors, including ESR2 (49). It may be instrumental to try and decrease the expression of miR-379-5p in SUFU-mutated tumors, which would increase the expression of FOXL2 and, therefore, the expression of ESR2, which may have chemoprotective effects.

Supporting evidence from an independent cohort. Since the current study reports only two patients, it needs to be repeated in a larger cohort. Larger independent SHH cohorts of tumors with known germline mutations are not publicly available, but we were able to detect an independent dataset of SHH tumors. Although this independent dataset does not show which patients have a germline mutation (*i.e.*, Gorlin's syndrome), it does include important phenotypic data, such as age and chromosomal deletions. We know from the literature that the majority of SHH MBs occur in infants younger than 3 years

Figure 3. Box plots of differentially expressed genes in patients under the age of three, who carry a deletion in 10q, which includes the SUFU gene ($n=3$), or in 9q, which contains the PTCH1 gene ($n=13$), according to the independent GSE85217 dataset (23). *t*-Test statistical significance: $*p\leq 0.05$, $**p\leq 0.01$, $***p\leq 0.001$.

(8). We chose to analyze data from these infants with tumors who carry a deletion in 10q or 9q (which include SUFU and PTCH1, respectively), adding significant support to our results. We assumed that the PTCH1- and SUFU-loss tumors will have a genetic expression similar to that in our patients. Of the 111 differentially expressed genes that we detected in our patients, 54 were also included in the microarray used in the GSE85217 dataset (available upon request). Of these, the expression of six genes (11%) was significantly different between PTCH1- and SUFU-loss tumors. These six genes are upregulated in the SUFU-loss tumors, which is in agreement with their expression in our SUFU-MB patient. Three of the six genes (GABRA4, NPNT, and PCP4L1) are targets that demonstrated an inverse expression with miRs in our patients (Figure 3).

In vitro validation. To validate our findings, we utilized short interfering RNA (siRNA) to knockdown SUFU or PTCH1 expression on a Daoy MB cell line, and we tested the effect of the expression of selected genes that were differentially expressed between PTCH1- and SUFU-loss tumors. To test

knockdown efficiency, we quantified the PTCH1 and SUFU expression in transfected cells. The expression of PTCH1 and SUFU was reduced by 60% and 80%, respectively, in siRNA transfected cells (Figure 4A). Five genes were selected and their expression following PTCH1 and SUFU down-regulation was tested. The direction of change observed in the *in vitro* model was consistent with their change expression as observed in the PTCH1- and SUFU-loss tumors.

Conclusion

Most MBs are thought to develop sporadically, but inherited forms also exist, most often in children with SHH MB. Due to the rarity of germline mutations that predispose to MB our knowledge of heritable predisposition is incomplete. Indeed, while 30% of all MB patients belong to the SHH subgroup, only 2% are defined as having Gorlin syndrome and show germline mutations in the SHH pathway. Hence, it is inherently difficult to collect samples from a large number of patients with such mutations. However, despite this caveat, by

Figure 4. *In vitro* validation of gene expression. (A) Efficiency of *SUFU* and *PTCH* siRNA silencing. (B) *SUFU* and *PTCH* silencing influence on gene expression * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (one-tailed *t*-test), $n = 3$.

the detection of molecular differences between two SHH-MB tumors having different germline mutations, this study contributes to our understanding of the biology of heritable MB and suggested potential drug targetable pathways.

Treatment of MB usually involves chemotherapy and craniospinal irradiation with severe long-term effects on memory and cognition, growth and development, hearing and the risk of secondary malignancies. Much research is devoted to finding more successful and less damaging treatments for this disease. There are four subgroups of MB but the commonest in infancy is the SHH subgroup (50) of which approximately 20% will have germline mutations in *PTCH1* or *SUFU* (Gorlin syndrome) (9). Children with GS should not receive radiation and general protocols omit/delay radiation for infants until they reach three years of age. Alternative treatments for infant with MB and in particular in the context of GS are desperately needed. Children with GS-*SUFU* differ phenotypically from those with GS-*PTCH1* and even their MB differ with a poorer prognosis noted in the former and a higher rate of secondary malignancies (10).

Herein we explored the differences between the tumors from two infants both with SHH-MB that bear different germline mutations causing GS, and we used an unbiased whole-transcriptome sequencing to identify previously undetected potential therapeutic targets. Often the study of a rare genetic disease can have implications for research and treatment of a wider cohort of patients such as SHH-MB as a whole. In the same way that targeted therapy has been developed for *PTCH1*-mutated tumors (although, at the moment, relevant only for skeletally mature patients), we hope

that a suitable target will be found for those with downstream mutations, such as *SUFU* and *GLI* and for infant with MB in general. This report may stimulate interest among the MB community and hopefully result in international collaborations for further delineating the unique features of different groups within MB and the SHH group in particular.

Conflicts of Interest

The Authors declare no conflicts of interest.

Authors' Contributions

Conceptualization, M.S-D and H.T; supervision, M.S-D, A.P, T.L and N.G-C; recruiting patients, H.T, S.M and N.G-C; clinical information, H.T and S.F; formal analysis and investigation, S.G; laboratory experiments, N.P; writing—original draft preparation, S.G, H.T and M.S-D; writing—review and editing, all Authors.

Acknowledgements

This research was funded by Zanyvl and Isabelle Krieger Fund (Baltimore, MD) (N.G-C), and the Israel Cancer Association (N.G-C), and the Levi-Eshkol Fund, Ministry of Science, Technology & Space, Israel (grant number 3-12624) for providing S.G scholarship. The Authors also wish to acknowledge Dr. Ruty Mehrian-Shai from Sheba Medical Center for providing the Daoy cell line.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon request.

References

- Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N and Farndon PA: Complications of the naevoid basal cell carcinoma syndrome: Results of a population based study. *J Med Genet* 30(6): 460-464, 1993. PMID: 8326488. DOI: 10.1136/jmg.30.6.460
- Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, Bale AE and Bale SJ: Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. *Am J Med Genet* 69(3): 299-308, 1997. PMID: 9096761
- Divakaran R, Ranjit L and Joseph B: Gorlin-Goltz syndrome. *Bahrain Med Bull* 37: 195-197, 2015. DOI: 10.12816/0014447
- Smith MJ, Beetz C, Williams SG, Bhaskar SS, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG and Evans DG: Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. *J Clin Oncol* 32(36): 4155-4161, 2014. PMID: 25403219. DOI: 10.1200/JCO.2014.58.2569
- Foulkes WD, Kamihara J, Evans DGR, Brugières L, Bourdeaut F, Molenaar JJ, Walsh MF, Brodeur GM and Diller L: Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. *Clin Cancer Res* 23(12): e62-e67, 2017. PMID: 28620006. DOI: 10.1158/1078-0432.CCR-17-0595
- Falkenstein KN and Vokes SA: Transcriptional regulation of graded Hedgehog signaling. *Semin Cell Dev Biol* 33: 73-80, 2014. PMID: 24862856. DOI: 10.1016/j.semdb.2014.05.010
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 114(2): 97-109, 2007. PMID: 17618441. DOI: 10.1007/s00401-007-0243-4
- Ramaswamy V and Taylor MD: Medulloblastoma: From myth to molecular. *J Clin Oncol* 35(21): 2355-2363, 2017. PMID: 28640708. DOI: 10.1200/JCO.2017.72.7842
- Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtlér KW, Morrissy AS, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciú C, Lawerenz C, Chan JA, Varlet P, Guerrini-Rousseau L, Fufts DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart HK, Shringarpure SS, De La Vega FM, Bustamante CD, Ng HK, Perry A, MacDonald TJ, Hernáiz Driever P, Bendel AE, Bowers DC, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen TV, Rösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO and Pfister SM: Spectrum and prevalence of genetic predisposition in medulloblastoma: A retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncol* 19(6): 785-798, 2018. PMID: 29753700. DOI: 10.1016/S1470-2045(18)30242-0
- Guerrini-Rousseau L, Dufour C, Varlet P, Masliah-Planchon J, Bourdeaut F, Guillaud-Bataille M, Abbas R, Bertozzi AI, Fouyssac F, Huybrechts S, Puget S, Bressac-De Paillerets B, Caron O, Sevenet N, Dimaria M, Villebasse S, Delattre O, Valteau-Couanet D, Grill J and Brugières L: Germline SUFU mutation carriers and medulloblastoma: Clinical characteristics, cancer risk, and prognosis. *Neuro Oncol* 20(8): 1122-1132, 2018. PMID: 29186568. DOI: 10.1093/neuonc/nox228
- Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD and Kuehl J: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. *N Engl J Med* 352(10): 978-986, 2005. PMID: 15758008. DOI: 10.1056/NEJMoa042176
- Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D and Gilbertson RJ: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. *Lancet Oncol* 7(10): 813-820, 2006. PMID: 17012043. DOI: 10.1016/S1470-2045(06)70867-1
- Kieran MW, Chisholm J, Casanova M, Brandes AA, Aerts I, Bouffet E, Bailey S, Leary S, MacDonald TJ, Mechinaud F, Cohen KJ, Riccardi R, Mason W, Hargrave D, Kalambakas S, Deshpande P, Tai F, Hurh E and Geoerger B: Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. *Neuro Oncol* 19(11): 1542-1552, 2017. PMID: 28605510. DOI: 10.1093/neuonc/nox109
- Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zaparka M, König R, Beroukheim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM and ICGC PedBrain Tumor Project.: Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell* 25(3): 393-405, 2014. PMID: 24651015. DOI: 10.1016/j.ccr.2014.02.004
- Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A and Gajjar A: Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. *Oncotarget* 8(41): 69295-69302, 2017. PMID: 29050204. DOI: 10.18632/oncotarget.20619
- Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone P and Caldas C: Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA* 16(5): 991-1006, 2010. PMID: 20360395. DOI: 10.1261/rna.1947110
- Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat*

- Rev Drug Discov 16(3): 203-222, 2017. PMID: 28209991. DOI: 10.1038/nrd.2016.246
- 18 Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S and Caldas C: The shaping and functional consequences of the microRNA landscape in breast cancer. *Nature* 497(7449): 378-382, 2013. PMID: 23644459. DOI: 10.1038/nature12108
- 19 Hershkovitz-Rokah O, Geva P, Salmon-Divon M, Shpilberg O and Liberman-Aronov S: Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. *Oncotarget* 9(8): 7928-7941, 2018. PMID: 29487703. DOI: 10.18632/oncotarget.23974
- 20 Gershanov S, Toledano H, Michowiz S, Barinfeld O, Pinhasov A, Goldenberg-Cohen N and Salmon-Divon M: MicroRNA-mRNA expression profiles associated with medulloblastoma subgroup 4. *Cancer Manag Res* 10: 339-352, 2018. PMID: 29497332. DOI: 10.2147/CMAR.S156709
- 21 Anders S and Huber W: Differential expression analysis for sequence count data. *Genome Biol* 11(10): R106, 2010. PMID: 20979621. DOI: 10.1186/gb-2010-11-10-r106
- 22 Krämer A, Green J, Pollard J Jr and Tugendreich S: Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics* 30(4): 523-530, 2014. PMID: 24336805. DOI: 10.1093/bioinformatics/btt703
- 23 Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Contier C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambliss LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V and Taylor MD: intertumoral heterogeneity within medulloblastoma subgroups. *Cancer Cell* 31(6): 737-754.e6, 2017. PMID: 28609654. DOI: 10.1016/j.ccell.2017.05.005
- 24 Edgar R, Domrachev M and Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* 30(1): 207-210, 2002. PMID: 11752295. DOI: 10.1093/nar/30.1.207
- 25 Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43(7): e47, 2015. PMID: 25605792. DOI: 10.1093/nar/gkv007
- 26 Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, Eberhart CG, Dubuc A, Guetouche T, Cardentey Y, Bouffet E, Pomeroy SL, Marra M, Malkin D, Rutka JT, Korshunov A, Pfister S and Taylor MD: Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathol* 123(4): 615-626, 2012. PMID: 22057785. DOI: 10.1007/s00401-011-0899-7
- 27 Kaur R, Aiken C, Morrison LC, Rao R, Del Bigio MR, Rampalli S and Werbowetski-Ogilvie T: OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells. *Dis Model Mech* 8(10): 1295-1309, 2015. PMID: 26398939. DOI: 10.1242/dmm.020594
- 28 Wortham M, Jin G, Sun JL, Bigner DD, He Y and Yan H: Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells. *PLoS One* 7(4): e36211, 2012. PMID: 22558385. DOI: 10.1371/journal.pone.0036211
- 29 Boon K, Eberhart CG and Riggins GJ: Genomic amplification of orthodenticle homologue 2 in medulloblastomas. *Cancer Res* 65(3): 703-707, 2005. PMID: 15705863.
- 30 Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, Gupta T, Krishnatry R, Kannan S, Kurkure P, Deopujari C, Shetty P, Biyani N, Korshunov A, Pfister SM, Northcott PA and Shirsat NV: Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. *Neuro Oncol* 15(12): 1644-1651, 2013. PMID: 24203893. DOI: 10.1093/neuonc/not123
- 31 Zagozewski J, Shahriary GM, Morrison LC, Saulnier O, Stromecki M, Fresnoza A, Palidwor G, Porter CJ, Forget A, Ayrault O, Hawkins C, Chan JA, Vladiou MC, Sundaresan L, Arsenio J, Taylor MD, Ramaswamy V and Werbowetski-Ogilvie TE: An OTX2-PAX3 signaling axis regulates group 3 medulloblastoma cell fate. *Nat Commun* 11(1): 3627, 2020. PMID: 32686664. DOI: 10.1038/s41467-020-17357-4
- 32 Anagnostopoulos AK, Papatheanasiou C, Karamolegou K, Anastasiadou E, Dimas KS, Kontos H, Koutsopoulos A, Prodromou N, Tzortzatou-Stathopoulou F and Tsangaris GT: Proteomic studies of pediatric medulloblastoma tumors with 17p deletion. *J Proteome Res* 14(2): 1076-1088, 2015. PMID: 25543836. DOI: 10.1021/pr501219f
- 33 Mohan AL, Friedman MD, Ormond DR, Tobias M, Murali R and Jhanwar-Uniyal M: PI3K/mTOR signaling pathways in medulloblastoma. *Anticancer Res* 32(8): 3141-3146, 2012. PMID: 22843885.
- 34 Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res* 92(8): 827-839, 2003. PMID: 12730128. DOI: 10.1161/01.RES.0000070112.80711.3D
- 35 Rooprai HK, Rucklidge GJ, Panou C and Pilkington GJ: The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. *Br J Cancer* 82(1): 52-55, 2000. PMID: 10638966. DOI: 10.1054/bjoc.1999.0876
- 36 Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K and Vince GH: Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. *Neurosci Res* 60(1): 40-49, 2008. PMID: 17980449. DOI: 10.1016/j.neures.2007.09.009
- 37 R Yang X, Pfeiffer RM and Goldstein AM: Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the

- naevoid basal cell carcinoma syndrome. *J Med Genet* 43(4): e16, 2006. PMID: 16582078. DOI: 10.1136/jmg.2005.035006
- 38 Urošević M, Kempf W, Zagrodnik B, Panizzon R, Burg G and Dummer R: HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. *Clin Exp Dermatol* 30(4): 422-425, 2005. PMID: 15953086. DOI: 10.1111/j.1365-2230.2005.01790.x
- 39 Lu Y, Gao W, Zhang C, Wen S, Huangfu H, Kang J and Wang B: Hsa-miR-301a-3p Acts as an oncogene in laryngeal squamous cell carcinoma via target regulation of Smad4. *J Cancer* 6(12): 1260-1275, 2015. PMID: 26640587. DOI: 10.7150/jca.12659
- 40 Xia X, Zhang K, Cen G, Jiang T, Cao J, Huang K, Huang C, Zhao Q and Qiu Z: MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. *Oncotarget* 6(25): 21046-21063, 2015. PMID: 26019136. DOI: 10.18632/oncotarget.4124
- 41 Xia X, Zhang K, Luo G, Cen G, Cao J, Huang K and Qiu Z: Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. *Am J Transl Res* 9(4): 1886-1895, 2017. PMID: 28469793
- 42 Di Rosa M, Sanfilippo C, Libra M, Musumeci G and Malaguarnera L: Different pediatric brain tumors are associated with different gene expression profiling. *Acta Histochem* 117(4-5): 477-485, 2015. PMID: 25792036. DOI: 10.1016/j.acthis.2015.02.010
- 43 Mesnil M: Connexins and cancer. *Biol Cell* 94(7-8): 493-500, 2002. PMID: 12566222. DOI: 10.1016/s0248-4900(02)00025-4
- 44 Artesi M, Kroonen J, Bredel M, Nguyen-Khac M, Deprez M, Schoysman L, Poulet C, Chakravarti A, Kim H, Scholtens D, Seute T, Rogister B, Bours V and Robe PA: Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy. *Neuro Oncol* 17(3): 392-406, 2015. PMID: 25155356. DOI: 10.1093/neuonc/nou215
- 45 Lin WD, Chou IC, Lee NC, Wang CH, Hwu WL, Lin SP, Chao MC, Tsai Y and Tsai FJ: FOXL2 mutations in Taiwanese patients with blepharophimosis, ptosis, epicanthus inversus syndrome. *Clin Chem Lab Med* 48(4): 485-488, 2010. PMID: 20184535. DOI: 10.1515/CCLM.2010.100
- 46 Georges A, L'Hôte D, Todeschini AL, Auguste A, Legois B, Zider A and Veitia RA: The transcription factor FOXL2 mobilizes estrogen signaling to maintain the identity of ovarian granulosa cells. *Elife* 3: 2014. PMID: 25369636. DOI: 10.7554/eLife.04207
- 47 Belcher SM, Burton CC, Cookman CJ, Kirby M, Miranda GL, Saeed FO and Wray KE: Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity. *BMC Pharmacol Toxicol* 18(1): 63, 2017. PMID: 28877739. DOI: 10.1186/s40360-017-0160-7
- 48 Paces-Fessy M, Boucher D, Petit E, Pauthe-Briand S and Blanchet-Tournier MF: The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. *Biochem J* 378(Pt 2): 353-362, 2004. PMID: 14611647. DOI: 10.1042/BJ20030786
- 49 Kotaja N, Aittomäki S, Silvennoinen O, Palvimo JJ and Jänne OA: ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. *Mol Endocrinol* 14(12): 1986-2000, 2000. PMID: 11117529. DOI: 10.1210/mend.14.12.0569
- 50 Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, Gajjar A and Pfister SM: Medulloblastoma. *Nat Rev Dis Primers* 5(1): 11, 2019. PMID: 30765705. DOI: 10.1038/s41572-019-0063-6
- 51 Zhao S, Guo Y, Sheng Q and Shyr Y: Heatmap3: An improved heatmap package with more powerful and convenient features. *BMC Bioinformatics* 15(Suppl 10): P16, 2016. DOI: 10.1186/1471-2105-15-S10-P16

Received January 19, 2021

Revised February 11, 2021

Accepted February 15, 2021